Member Info for Saxondale

Phase 2 will start with dose optimization and is expected to enroll 28-32 patients randomized between two selected doses. Faron plans to increase the number of US clinical sites from two to five sites to accelerate study recruitment.

5 sites in the US , (plus the ones in Europe )( all probably AML focused hospital sites) - should see a rapid P2 trial , considering the data comes out almost immediately .

Today they should really clarify for us who is going to be assisting us in this -The usual reply we get is 'Don't worry about that we have it in hand ' .

But if they are telling us how they plan to run the next 6-9 months - they will have to tell us how it is being funded surely .

Should be interesting

To put it into context -this data is really good .

A quick search on the efficacy of AZA on its own -

Complete remission (CR) was achieved in 14% of MDS, 7% of AML and 10% of CMML patients. Overall response rate was following: 27% for MDS, 20% for AML and 20% for CMML.

Faron are achieving superb responses .

Couldn't ask for better results - Green light for any partner now .

P2 to start imminently

Just need that other RNS to address the elephant in the room now .

Top for the day that is , was hoping to buy them back when it sagged .

That 90% is sitting in for the big money by the way .

I sold 10% today at £1.41 . Thought that was the top .

I've still got 90% in . Can't pick the bottom , and now I can't pick the top either lol

You remember we had weeks of 1's endlessly all day long lasy tear and we usually got sweet FA lol.

Maybe this one is it !

I'm not making any wild guesses that Weds could be ' THE DAY ' . I doubt it will be .

But , and it's a big but , I'm assuming that if they are making a bit of a event around this latest data , then it will be 'as good' if not ' better' than what they've been getting .

If we hadn't had the shuffle of MLF , and the appointment of CR recently , you might expect the usual ' we need more data ' before ..... spiel . But somethings being worked out behind the scenes in strategy I'm sure . You don't need to be Sherlock Holmes to work that out .

Faron need funding to continue . Bayer have a huge chequebook and their head of their Oncology Strategic Unit has just taken a seat on our board . Talk about putting you towel on the sunlounger ( they are Germans after all lol !)

The insertion of Bayers top Oncology business honcho Christine Roth into little old Faron just doesn't make sense unless she will be part of some kind of transition , in my opinion.

Likewise the sudden change in CMO - just as the best data is just emerging .

I just can't understand why CR would join Farons BOD unless they had ambitions in that direction .

Despite the fact I'm always uber optimistic here - it's pretty clear something is finally going to happen here at last .

Just a thought regards these moves within the board. A similar situation is in place over at Avacta , where they have taken on a highly regarded consultant to oversee the program whilst they seek a full time CMO .

They too are on the verge of detailing their P1 data , also known to be groundbreaking .

Any potential buyer/partner - will be needing to justify any large buyout/spend to their own shareholders . And that will require Faron and Avacata to demonstrate that the incoming investment is justified.

So perhaps these management position changes and the very quick move to update us all with this data presentation is being led by the potential suitor in order for them to satisfy their own board that a deal is both value for money and a great move .

Laying out the latest data from Bexmab should tick all the boxes .

The only other major piece of the jigsaw would be the FDA recommendations surrounding Bex and AML .

But If they are presenting us the plans for the next 6-9 months next week , you'd assume they know what they are.

66m shares - £221 million Mcap.

£1billion Mcap would give us a £15 share price

I think Faron see their platform as being in that kind of valuation as a minimum - the more they prove up the bigger the price .

All depends on how they cut the cake up ( licensing deals etc ) , or sell the whole shebang ( my preferred option lol )

A pile of new dates added to their calendar today .

Busy Autumn for the team.

https://www.faron.com/investors/event-calendar

These Big companies are all circling around the small successful biotech companies that have clinical trials in oncology that have platforms that can be multiplied in value in the future .

Now at Faron , Bayer have pulled up a chair and have a thumb on the corner of the paperwork should anyone try and muscle in .

I'm intrigued as to what is really going on here . They rarely announce data coming in advance .

Theres definitely something big going on in the background for sure .

Like you say - you don't change your Chief Medical Officer , and put her on the board , along with adding Bayers oncology business head honcho , then appoint an interim CMO ( of high calibre) , all at the same time in a study when you are getting absolutely stunning data , which is coming thick and fast , with full recruitment , without good reason .

You then announce a week in advance that you will update everyone with the latest data and your plans for the next 6-9 months .

So update coming next Weds .

I wonder if they'll release the info beforehand . Back in July it came on the same day .

So a week to wait I'd say .

Should be good otherwise why promote its arrival .

Looking forward to it ;-)

Back in here again . This time at 9.47p .

Bit of a discount from the 50p days when I first dipped my toe in .

Yes , the new NED certainly has an incentive to get this higher .

And at £19.97m Mcap - certainly room to grow .

Plays ok for me on the Vox website.

He sounds confident ( as you would expect) .

He does know his onions , on how to get this company and the drugs through to approval .

Good to have a guy at the helm who is not just concerned about the science , but on really not missing the opportunities .

Faron recently announced they planned to file for BLA in 2025 a while ago , and that didn't do them or their SP any harm - in fact it cemented the robustness of the data they have and the confidence in the plan.

Like Dogs says - they'll be bought out / partnered up way before then $$$

I don't watch the Sp like a hawk , and you never can time every top up perfectly . I know the SP is being decimated , and having a long term plan here , I just see that as helping me build a position .When I have some funds , I take a look , and if the prospects are still as attractive , I add away .

I guess I could sit and just wait with a load of cash for the final low point - but how am I going to time that ?

Got my average down again today - so that's good enough for me .

Just had a nice top up again .

6.34p

Crazy that last time the SP was this low was April 2020 - when GGP were still just scratching the surface so to speak .

So much value added in those 3 and a half years .

Months away from hitting the ore now , yet here we are at 6.5p .

Every month I'm adding more while we are down here .

One benefit of having read every document since 2020 is that buying shares at this price is even more pleasing .

I think the current uncertainty in the markets , and the fact that it is getting harder to raise money means that the Nas may be on the back burner for now ( as far a value for money for shareholders ). It was wise to prepare for it , which I'm sure they have - so that should it be needed , they could go down that route .

But its only been in the last couple of months that this stunning Bexmab data has changed the landscape .

All of a sudden we have Christine Roth from Bayer appear on the board .

MLF moves away from CMO onto board .

A new interim CMO.

Something is cooking , and we haven't seen the finished article yet .

FDA meeting was supposed to be Q3 - that would lay out the pathway for Bex ( accelerated Approval ?)

Have they had it yet ?

These big Pharma takeovers are often triggered by something smaller finally getting someone to pull the pin .

Bexmab may be that .

In the end , I think whoever makes a move I think will be wanting not just the AML market for Bex , but the whole platform .

Because that's where the big money will be made .